The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study
Abstract
Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Nosocomial infections in medical intensive care units in the United States
Richards, M. J., Edwards, J. R., Culver, D. H., & Gaynes, R. P. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00020 · Cited by 1,565
Impact of BAL Data on the Therapy and Outcome of Ventilator-Associated Pneumonia
Luna, C. M., Vujacich, P., Niederman, M. S., Vay, C., Gherardi, C., Matera, J., & Jolly, E. C. (1997) · Chest · doi:10.1378/chest.111.3.676 · Cited by 916
Ventilator-associated Pneumonia Caused by Potentially Drug-resistant Bacteria
TROUILLET, J.-L., CHASTRE, J., VUAGNAT, A., JOLY-GUILLOU, M.-L., COMBAUX, D., DOMBRET, M.-C., & GIBERT, C. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.2.9705064 · Cited by 885
(1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.5.8630626 · Cited by 830
Methicillin-Resistant Staphylococcus aureus in U.S. Hospitals, 1975–1991
Panlilio, A. L., Culver, D. H., Gaynes, R. P., Banerjee, S., Henderson, T. S., Tolson, J. S., Martone, W. J., & System, N. N. I. S. (1992) · Infection Control & Hospital Epidemiology · doi:10.1086/646432 · Cited by 657
Alvarez-Lerma, F., & ICU-Acquired Pneumonia Study Group (1996) · Intensive Care Medicine · doi:10.1007/bf01712153 · Cited by 652
Brickner, S. J., Hutchinson, D. K., Barbachyn, M. R., Manninen, P. R., Ulanowicz, D. A., Garmon, S. A., Grega, K. C., Hendges, S. K., Toops, D. S., Ford, C. W., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9509556 · Cited by 582
Guideline for Prevention of Nosocomial Pneumonia
Tablan, O. C., Anderson, L. J., Arden, N. H., Breiman, R. F., Butler, J. C., McNeil, M. M., & The Hospital Infection Control Practices Advisory Committee (1994) · Infection Control and Hospital Epidemiology · doi:10.2307/30147436 · Cited by 500
Cited by
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Community-associated meticillin-resistant Staphylococcus aureus
DeLeo, F. R., Otto, M., Kreiswirth, B. N., & Chambers, H. F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61999-1 · Cited by 1,506
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
Wunderink, R. G., Niederman, M. S., Kollef, M. H., Shorr, A. F., Kunkel, M. J., Baruch, A., McGee, W. T., Reisman, A., & Chastre, J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir895 · Cited by 570
Self-citationStevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H., Hafkin, B., & the Linezolid MRSA Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/340353 · Cited by 506
Self-citationLinezolid: The First Oxazolidinone Antimicrobial
Moellering, R. C. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00015 · Cited by 455
Tenover, F. C., & Moellering, R. C. (2007) · Clinical Infectious Diseases · doi:10.1086/513203 · Cited by 452
Hematologic Effects of Linezolid: Summary of Clinical Experience
Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., & Kuter, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2723-2726.2002 · Cited by 443
Gemmell, C. G., Edwards, D. I., Fraise, A. P., Gould, F. K., Ridgway, G. L., & Warren, R. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl017 · Cited by 439
Elyasi, S., Khalili, H., Dashti-Khavidaki, S., & Mohammadpour, A. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1259-9 · Cited by 436
Diekema, D. J., & Jones, R. N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06964-1 · Cited by 378
Linezolid: The First Oxazolidinone Antimicrobial
Paterson, D. L., Pasculle, A. W., & McCurry, K. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00017 · Cited by 328
Masterton, R. G., Galloway, A., French, G., Street, M., Armstrong, J., Brown, E., Cleverley, J., Dilworth, P., Fry, C., Gascoigne, A. D., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn162 · Cited by 325
Wunderink, R. G., Rello, J., Cammarata, S. K., Croos-Dabrera, R. V., & Kollef, M. H. (2003) · Chest · doi:10.1016/s0012-3692(15)33412-7 · Cited by 317
Self-citationKollef, M. H., Rello, J., Cammarata, S. K., Croos-Dabrera, R. V., & Wunderink, R. G. (2004) · Intensive Care Medicine · doi:10.1007/s00134-003-2088-1 · Cited by 315
Self-citationPneumonia Caused by Methicillin‐Resistant Staphylococcus aureus
Rubinstein, E., Kollef, M. H., & Nathwani, D. (2008) · Clinical Infectious Diseases · doi:10.1086/533594 · Cited by 313
Self-citationLipsky, B. A., Itani, K., Norden, C., & the Linezolid Diabetic Foot Infections Study Group (2004) · Clinical Infectious Diseases · doi:10.1086/380449 · Cited by 311
Self-citationRayner, C. R., Forrest, A., Meagher, A. K., Birmingham, M. C., & Schentag, J. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00007 · Cited by 306
Rotstein, C., Evans, G., Born, A., Grossman, R., Light, R. B., Magder, S., McTaggart, B., Weiss, K., & Zhanel, G. G. (2008) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/593289 · Cited by 282
Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections
Perry, C. M., & Jarvis, B. (2001) · Drugs · doi:10.2165/00003495-200161040-00008 · Cited by 275
Serious Infections Caused by Methicillin‐Resistant Staphylococcus aureus
Boucher, H., Miller, L. G., & Razonable, R. R. (2010) · Clinical Infectious Diseases · doi:10.1086/653519 · Cited by 252
Powers, J. H., Patrick, D. L., Walton, M. K., Marquis, P., Cano, S., Hobart, J., Isaac, M., Vamvakas, S., Slagle, A., Molsen, E., et al. (2017) · Value in Health · doi:10.1016/j.jval.2016.11.005 · Cited by 191
Penetration of Vancomycin into Epithelial Lining Fluid in Healthy Volunteers
Lodise, T. P., Drusano, G. L., Butterfield, J. M., Scoville, J., Gotfried, M., & Rodvold, K. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00712-11 · Cited by 60
Metadata
- Authors
- Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., & the Linezolid Nosocomial Pneumonia Study Group
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-02-01
- Volume
- 32
- Issue
- 3
- Pages
- 402-412
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2128076923
- Cited by
- 440
- References
- 46
- FWCI
- 30.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.